EVALUATION OF ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY OF OXAPROZIN IN SWISS ALBINO MICE

Depression is a prevalent mental illness. According to estimates, 5 percent of adults worldwide experience depression. Depression affects more women than males. Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory medication (NSAID) used to treat osteoarthritis and rheumatoid arthritis-related inflammation, edoema, stiffness, and joint discomfort. The present study is based on the evaluation of antidepressant and anxiolytic activity of oxaprozin in Swiss albino (either sex) weight 20-25 gm were procured from ICAR-Indian Veterinary Research Institute (ICAR-IVRI), Izzat nagar, Bareilly, Uttar Pradesh. All the mice were divided into 4 groups (n=6) i.e., normal control which was given normal saline, positive control given Imipramine (10mg/kg, i.p.) and diazepam (10mg/kg, subcutaneously), test 1given oxaprozin(10mg/kg, p.o.) and test 2 given Oxaprozin (20mg/kg, p.o.) up to 7 days. The anxiolytic and antidepressant activity were evaluated by parameters i.e., elevated plus maze, FST, rota-rod test and biochemical parameters. It resulted that oxaprozin demonstrates anxiolytic and antidepressant activity. It exhibits antidepressant action probably by facilitating the release of neurotransmitters i. e., serotonin, dopamine. It also increases the release of GABA (Gamma Amino Butyric Acid) and chloride ions influx that leads to hyperpolarization .In conclusion, Oxaprozin is a predominant anxiolytic & anti-depressant drug. It can be effectively used in the treatment of depression, mental agitation and other neurological disorders after successfully evaluating mechanism of action against the same.This study refers, that it might be used in the treatment of depression among human beings after clinical trials.